Entrada Therapeutics (TRDA) Revenue & Revenue Breakdown
Entrada Therapeutics Revenue Highlights
Latest Revenue (Y)
$129.01M
Latest Revenue (Q)
$94.69M
Main Segment (Y)
License
Entrada Therapeutics Revenue by Period
Entrada Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $129.01M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Entrada Therapeutics generated $129.01M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Entrada Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $94.69M | 60.17% |
| 2024-03-31 | $59.12M | 41.27% |
| 2023-12-31 | $41.85M | -4.31% |
| 2023-09-30 | $43.73M | 140.70% |
| 2023-06-30 | $18.17M | -28.07% |
| 2023-03-31 | $25.26M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | - |
Entrada Therapeutics generated $94.69M in revenue during Q2 2024, up 60.17% compared to the previous quarter, and up 374.88% compared to the same period a year ago.
Entrada Therapeutics Revenue Breakdown
Entrada Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 |
|---|---|
| License | $139.00M |
Entrada Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|---|
| License | $70.90M | $157.90M | - | $211.60M | - | - |
| Upfront Payment Revenue | - | - | - | $39.80M | $14.63M | - |
Entrada Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License (100.00%).
Entrada Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TRDA | Entrada Therapeutics | $129.01M | $94.69M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| OPT | Opthea | $108.41K | $61.27K |
| CGEM | Cullinan Oncology | - | - |
| PHVS | Pharvaris | - | - |
| RLYB | Rallybio | - | $299.00K |
| IRON | Disc Medicine | - | - |
| ELYM | Eliem Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| LRMR | Larimar Therapeutics | - | - |
| PRDS | Pardes Biosciences | - | - |
| VIGL | Vigil Neuroscience | - | - |
| THRD | Third Harmonic Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| GNTA | Genenta Science S.p.A. | - | - |
| PEPG | PepGen | - | - |
| TYRA | Tyra Biosciences | - | - |
TRDA Revenue FAQ
What is Entrada Therapeutics’s yearly revenue?
Entrada Therapeutics's yearly revenue for 2023 was $129.01M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. TRDA's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Entrada Therapeutics’s quarterly revenue?
Entrada Therapeutics's quarterly revenue for Q2 2024 was $94.69M, a 60.17% increase from the previous quarter (Q1 2024), and a 421.16% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $59.12M, a 41.27% increase from the previous quarter (Q4 2023), and a 134.05% increase year-over-year (Q1 2023). TRDA's quarterly revenue for Q4 2023 was $41.85M, a -4.31% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Entrada Therapeutics’s revenue growth rate?
Entrada Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.
What are Entrada Therapeutics’s revenue streams?
Entrada Therapeutics's revenue streams in c 23 are License
What is Entrada Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Entrada Therapeutics was License. This segment made a revenue of $139M, representing 100.00% of the company's total revenue.